Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
Drug combination without chemotherapy can be effective in treating older patients with Ph+ ALL

Drug combination without chemotherapy can be effective in treating older patients with Ph+ ALL

Potential association between senescence and aging in COVID-19

Potential association between senescence and aging in COVID-19

Clearing old, dysfunctional cells in fat alleviates diabetes

Clearing old, dysfunctional cells in fat alleviates diabetes

Cancer drugs could be repurposed as potential therapies for Alzheimer's disease

Cancer drugs could be repurposed as potential therapies for Alzheimer's disease

Celastrol shows potential anti-SARS-CoV-2 activity

Celastrol shows potential anti-SARS-CoV-2 activity

Study sheds light on potential new treatment approach in AML patients

Study sheds light on potential new treatment approach in AML patients

YAP signal pathway plays a vital role in the onset of head-and-neck cancer

YAP signal pathway plays a vital role in the onset of head-and-neck cancer

First randomized clinical trial compares targeted therapies for acute lymphoblastic leukemia

First randomized clinical trial compares targeted therapies for acute lymphoblastic leukemia

Researchers discover new chemical weapon to fight against cancer

Researchers discover new chemical weapon to fight against cancer

Physicians more likely to prescribe drugs of manufacturers who paid them money

Physicians more likely to prescribe drugs of manufacturers who paid them money

New findings from a safety and feasibility clinical trial on removal of senescent cells

New findings from a safety and feasibility clinical trial on removal of senescent cells

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

New system for anti-cancer drug delivery offers hope to treat pediatric tumors

New system for anti-cancer drug delivery offers hope to treat pediatric tumors

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Researchers test new cancer research model that may reduce cost and speed up studies

Researchers test new cancer research model that may reduce cost and speed up studies

Mayo Clinic study reveals link between senescent cells and bone loss in mice

Mayo Clinic study reveals link between senescent cells and bone loss in mice

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

Mayo Clinic researchers discover three new senolytic drugs

Mayo Clinic researchers discover three new senolytic drugs

Mayo Clinic study finds link between biology of aging and idiopathic pulmonary fibrosis

Mayo Clinic study finds link between biology of aging and idiopathic pulmonary fibrosis

Research findings point to inherited genetic basis of ALL risk in children

Research findings point to inherited genetic basis of ALL risk in children